ESR1 and triple-negative breast carcinoma: We treated triple-negative breast cancer cell line (MDA-MB-231), estrogen-receptor lacking breast cancer line (MCF7) and normal breast epithelial cell line (MCF10A) with 20 μM cisplatin for four hours.